Cresco Labs Solid Q2 Performance and Debt Refinancing Strengthen Foundation for Long-Term Value Creation

Executive Summary

• Cresco Labs Inc. reported financial and operating results for the second quarter ended June 30, 2025, highlighting a net loss of $14 million driven by non-cash impairment charges.
• The company achieved second-quarter revenue of $164 million and generated $9 million in operating cash flow, while maintaining its No. 1 market share position in multiple billion-dollar markets.
• Management announced a significant balance sheet milestone: signing a commitment letter to refinance existing debt with a new $325 million term loan, aimed at preserving equity value and creating financial flexibility.

Key Details

• Revenue: $164 million (specifically $163,624,000) for Q2 2025, compared to $184,356,000 in Q2 2024.
• Gross Profit: $83 million (specifically $83,256,000); Adjusted Gross Profit of $83 million with an Adjusted Gross Margin of 50.6%.
• Operating Expenses: SG&A was $51 million (31.4% of revenue); Adjusted SG&A was $49.5 million (30.3% of revenue).
• Net Income/Loss: Net loss of $14 million (specifically $13,893,000), which includes $9.3 million in non-cash impairment charges related to California assets held for sale.
• EBITDA Metrics: Adjusted EBITDA was $41 million (specifically $40,876,000) with an Adjusted EBITDA margin of 25.0%.
• Cash Flow: Operating cash flow was $9 million (specifically $8,831,000); Free Cash Flow was negative $3.8 million (specifically -$3,842,000).
• Balance Sheet & Liquidity:
  • Cash and cash equivalents: $147 million (specifically $146,609,000).
  • Senior secured term loan debt (net): $354 million.
  • Mortgage loan (net): $18 million.
  • Total shares on a fully converted basis: 483,444,948 Subordinate Voting Shares.
• Debt Refinancing: Signed a commitment letter for a new $325 million term loan to refinance existing debt, intended to strengthen the balance sheet and provide long-term financial flexibility.
• Strategic Outlook: Management indicated the cannabis industry is entering a phase of consolidation and rationalization, with Cresco remaining opportunistic for M&A in productive states while maintaining a disciplined approach.

Notable Quotes

• Management Commentary: "In Q2, we delivered solid performance in line with guidance, maintained our market share in a highly competitive environment, and continued to drive cash flow through operational discipline. Crucially, we signed a commitment letter to refinance our debt with a new $325 million term loan. This milestone reinforces our balance sheet, preserves our equity value and creates financial flexibility for years to come."
• Management Commentary: "The cannabis industry is entering a new phase, defined by consolidation and rationalization. We’re seeing more opportunities for M&A in very productive states that will be incremental for Cresco. As previously stated, we’re going to be opportunistic while staying patient and disciplined so we can invest in sustainable growth when the right opportunities arise."